This phase I dose-escalation study evaluated the safety and pharmacokinetics of intravenous zinc supplementation in critically ill pediatric patients. Conducted at a single center, the study enrolled 10 children aged 1–17 years with systemic inflammatory response syndrome (SIRS) or sepsis. Participants received escalating doses of intravenous zinc chloride (0.25, 0.5,
